Indeed, a spectrum of clinical presentations including area postrema, diencephalic, brainstem and symptomatic cerebral syndrome has been associated with AQP4-IgG antibodies, leading to renaming of NMO to NMOSD [4,5]. This evidence concerns the gene AQP4 and neuromyelitis optica.